NCT01662791View on ClinicalTrials.gov

Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

March 31, 2015

Conditions

Parkinson's Disease

Interventions

DRUG

Rifaximin

All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale